AzTrials
AzTrials

Urinary Bladder, OveractivePhase 4SOFIANCT00798434

A Study to Compare the Effectiveness and Safety of Fesoterodine and Placebo in an Elderly Population of Patients Who go to the Toilet Very Frequently Due to Overactive Bladder.

A Phase 4 study testing Fesoterodine fumarate in people with Urinary Bladder, Overactive, run by Pfizer at 60 sites in 15 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The drug being studied, fesoterodine fumarate helps prevent the bladder neck opening at unwanted times and has been shown to help patients with overactive bladder syndrome pass urine less frequently than before treatment. Read more about this study

Who is it for?
Ages 65 years and older
Conditions the study is for
Urinary Bladder, Overactive
What is being tested?
Fesoterodine fumarate
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
794 participants
Where
60 sitesin 15 countries
Study dates
Jun 2008to Sep 2010
Phase
Phase 4
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 65 years and older
  • All sexes
  • No healthy volunteers
  • Older adult

Who may be able to join

  • Male or female ≥65 years old.
  • Overactive bladder symptoms for at least 3 months prior to study start.
  • Eight or more micturitions per 24 hours as confirmed by diary records

Who cannot join

  • Predominant Stress Urinary Incontinence
  • Active or recurrent bladder infections
  • Other bladder and genital conditions that could be the predominant cause of symptoms or interfere with treatment assessment and success.

Trial locations and contacts

60 sites in 15 countries.

60 sites in 15 countries

United Kingdom7 sites
  • Pfizer Investigational Site

    Bexhill-on-Sea, East Sussex, TN39 4SP

  • Pfizer Investigational Site

    Birmingham, B17 0AA

  • Pfizer Investigational Site

    Harrow, Middlesex, HA1 3UJ

  • Pfizer Investigational Site

    High Heaton, Newcastle upon Tyne, NE7 7DN

  • Pfizer Investigational Site

    Leytonstone, London, E11 1NR

  • Pfizer Investigational Site

    London, W2 1NY

  • Pfizer Investigational Site

    London, WC1E 6AU

Other trials in United Kingdom

Germany6 sites
  • Pfizer Investigational Site

    Berlin, 10249

  • Pfizer Investigational Site

    Berlin, 14052

  • Pfizer Investigational Site

    Frankfurt, 60435

  • Pfizer Investigational Site

    Hanover, 30625

  • Pfizer Investigational Site

    Leipzig, 04109

  • Pfizer Investigational Site

    München, 81927

Other trials in Germany

Sweden6 sites
  • Pfizer Investigational Site

    Eslöv, 241 23

  • Pfizer Investigational Site

    Gothenburg, 416 85

  • Pfizer Investigational Site

    Malmö, 211 20

  • Pfizer Investigational Site

    Malmö, 211 52

  • Pfizer Investigational Site

    Norrköping, 601 82

  • Pfizer Investigational Site

    Stockholm, 141 86

Other trials in Sweden

Finland5 sites
  • Pfizer Investigational Site

    Helsinki, 00290

  • Pfizer Investigational Site

    Kouvola, 45200

  • Pfizer Investigational Site

    OYS, 90029

  • Pfizer Investigational Site

    Tampere, 33521

  • Pfizer Investigational Site

    Turku, 20100

Other trials in Finland

Portugal5 sites
  • Pfizer Investigational Site

    Coimbra, 3000-075

  • Pfizer Investigational Site

    Lisbon, 1990-273

  • Pfizer Investigational Site

    Porto, 4050-011

  • Pfizer Investigational Site

    Porto, 4099-005

  • Pfizer Investigational Site

    Porto, 4200-319

Other trials in Portugal

Slovakia5 sites
  • Pfizer Investigational Site

    Bratislava, 851 01

  • Pfizer Investigational Site

    Bratislava, 851 05

  • Pfizer Investigational Site

    Galanta, 924 22

  • Pfizer Investigational Site

    Košice, 040 11

  • Pfizer Investigational Site

    Kosice - Saca, 040 15

Other trials in Slovakia

Spain5 sites
  • Pfizer Investigational Site

    Getafe, Madrid, 28905

  • Pfizer Investigational Site

    Manacor, Palma de Mallorca, 07500

  • Pfizer Investigational Site

    Martorell, Barcelona, 08760

  • Pfizer Investigational Site

    Sabadell, Barcelona, 08208

  • Pfizer Investigational Site

    Valencia, Valencia, 46009

Other trials in Spain

Belgium4 sites
  • Pfizer Investigational Site

    Antwerp, 2060

  • Pfizer Investigational Site

    Edegem, B-2650

  • Pfizer Investigational Site

    Ghent, B-9000

  • Pfizer Investigational Site

    Kortrijk, 8500

Other trials in Belgium

Norway4 sites
  • Pfizer Investigational Site

    Hamar, 2317

  • Pfizer Investigational Site

    Oslo, NO-0257

  • Pfizer Investigational Site

    Tønsberg, 3103

  • Pfizer Investigational Site

    Trondheim, 7006

Other trials in Norway

Turkey (Türkiye)4 sites
  • Pfizer Investigational Site

    Ankara, 06100

  • Pfizer Investigational Site

    Istanbul, 34098

  • Pfizer Investigational Site

    Izmir, 35100

  • Pfizer Investigational Site

    Samsun, 55200

Other trials in Turkey (Türkiye)

Israel3 sites
  • Pfizer Investigational Site

    Haifa, 31096

  • Pfizer Investigational Site

    Haifa, 34362

  • Pfizer Investigational Site

    Jerusalem, 91031

Other trials in Israel

Denmark2 sites
  • Pfizer Investigational Site

    Aarhus N, 8200

  • Pfizer Investigational Site

    Glostrup Municipality, 2600

Other trials in Denmark

Italy2 sites
  • Pfizer Investigational Site

    Foggia, 71100

  • Pfizer Investigational Site

    Terracina, LT, 04019

Other trials in Italy

Austria1 site
  • Pfizer Investigational Site

    Vienna, 1090

Other trials in Austria

Switzerland1 site
  • Pfizer Investigational Site

    Frauenfeld, CH-8501

Other trials in Switzerland

About this study

Official title: A 24-Week, Multi-Centre Trial, Comprising A 12-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Phase Followed By A 12-Week Open-Label Phase, To Evaluate The Efficacy And Safety Of A Fesoterodine Flexible Dose Regimen In Elderly Patients With Overactive Bladder.

The drug being studied, fesoterodine fumarate helps prevent the bladder neck opening at unwanted times and has been shown to help patients with overactive bladder syndrome pass urine less frequently than before treatment. It is postulated that this drug will also prove effective in elderly patients (aged > 65 years) and that the ability to change dose between 4 and 8mg will allow each patient to have an optimised treatment.

Being tested
Placebo, Fesoterodine fumarate
Keywords
Overactive bladder syndrome, fesoterodine, elderly, flexible dose regimen, urgency, frequency, urge urinary incontinence, anticholinergic, antimuscarinic
Medical subject headings
Urinary Bladder, Overactive, Urinary Incontinence, Urge

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PlaceboDrug

    placebo administered orally in the morning or evening.

  • Fesoterodine fumarateDrug

    Also called Toviaz

    Fesoterodine fumarate is an antimuscarinic drug recently approved by the European Medicines Evaluation Agency for treatment of symptoms of overactive bladder syndrome.

Study groups in NCT00798434
Study groupRoleWhat they receive
PlaceboActive comparatorFlexible dose regimen of placebo once daily. The dose can be increased after 4 weeks if clinically indicated. Subsequently the dose can be reduced to the original dose if clinically indicated.
Receives: Drug: Placebo
FesoterodineActive comparatorFlexible dose regimen of fesoterodine fumarate 4mg once daily. The dose can be increased to 8mg once daily after 4 weeks if clinically indicated. Subsequently the dose can be reduced to 4mg if clinically indicated.
Receives: Drug: Fesoterodine fumarate

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change From Baseline in Number of Micturition-Related Urgency Episodes Per 24 Hours at Week 12

    Number of micturition-related urgency episodes per 24 hours calculated as number of micturitions with USS rating of greater than or equal to (>=) 3 divided by number of days that diary data was collected at that visit. USS ranged 1 to 5 (1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine). Change = observation minus baseline, where lower scores were an improvement/decrease in micturition-related urgency episodes.

    Measured: Baseline and Week 12

Secondary outcomes (30)
  1. Percent Change From Baseline in Micturition-Related Urgency Episodes Per 24 Hours at Weeks 4, 8, and 12

    Micturition-related urgency episodes per 24 hours defined as those with USS Scale rating of >=3 marked for corresponding micturition in diary. USS rating of 3: Moderate feeling of urgency, 4: Severe feeling of urgency, 5: Unable to hold; leak urine. Percent change calculated as: 100* (Urgency Episode at Week x - baseline)/baseline. Change = observation minus baseline, where lower scores were an improvement/decrease in micturition-related urgency episodes.

    Measured: Baseline and Weeks 4, 8, and 12

  2. Change From Baseline in Mean Number of Severe Micturition-Related Urgency Episodes Per 24 Hours at Weeks 4, 8, and 12

    Severe micturition-related urgency episodes defined as those with the USS rating >=4. USS rating of 4: Severe feeling of urgency and 5: Unable to hold; leak urine. Change = observation minus baseline, where lower scores were an improvement/decrease in severity of micturition-related urgency episodes.

    Measured: Baseline and Weeks 4, 8, and 12

  3. Percent Change From Baseline of Severe Micturition-Related Urgency Episodes Per 24 Hours at Weeks 4, 8, and 12

    Severe micturition-related urgency episodes defined as those with USS rating >=4. USS rating of 4: Severe feeling of urgency and 5: Unable to hold; leak urine. Change = observation minus baseline, where lower scores were an improvement/decrease in severity of micturition-related urgency.

    Measured: Baseline and Weeks 4, 8, and 12

  4. Change From Baseline in Mean Number of Micturitions Per 24 Hours at Weeks 4, 8, and 12

    Micturitions included episodes of voluntary micturition and episodes of UUI, defined as those micturitions with USS rating of 5 (unable to hold; leak urine) in the diary of participants with UUI at baseline. Change = observation minus baseline, where lower scores were an improvement/decrease in micturitions.

    Measured: Baseline and Weeks 4, 8, and 12

  5. Percent Change From Baseline in Micturitions Per 24 Hours at Weeks 4, 8, and 12

    Micturitions included episodes of voluntary micturition and episodes of UUI. Change = observation minus baseline, where lower scores were an improvement/decrease in micturitions.

    Measured: Baseline and Weeks 4, 8, and 12

  6. Change From Baseline in Number of Nocturnal Micturitions Per 24 Hours at Weeks 4, 8, and 12

    Nocturnal micturitions defined as micturitions with USS rating 1-5 that occurred between time participant went to bed and time he or she arose to start the next day. USS rating: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine. Calculated as number of nocturnal micturitions divided by number of diary days collected at that visit. Change = observation minus baseline, where lower scores were an improvement/decrease in nocturnal micturitions.

    Measured: Baseline and Weeks 4, 8, and 12

  7. Percent Change From Baseline in Nocturnal Micturitions Per 24 Hours at Weeks 4, 8, and 12

    Nocturnal micturitions defined as micturitions with USS rating 1-5 that occurred between time participant went to bed and time he or she arose to start the next day. USS rating: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine. Change = observation minus baseline, where lower scores were an improvement/decrease in nocturnal micturitions.

    Measured: Baseline and Weeks 4, 8, and 12

  8. Change From Baseline in Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Weeks 4, 8, and 12

    UUI episodes defined as those with USS rating of 5 (unable to hold; leak urine) in the diary. Change = observation minus baseline, where lower scores were an improvement/decrease in UUI episodes.

    Measured: Baseline and Weeks 4, 8, and 12

  9. Percent Change From Baseline of UUI Episodes Per 24 Hours at Weeks 4, 8, and 12

    UUI episodes defined as those with the USS rating of 5 (unable to hold; leak urine)in the diary. Change = observation minus baseline, where lower scores were an improvement/decrease in UUI episodes.

    Measured: Baseline and Weeks 4, 8, and 12

  10. Change From Baseline in Daily Sum Rating in USS at Weeks 4, 8, and 12

    USS total range 1 to 5 (1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine). Change = observation minus baseline, where lower scores were an improvement/decrease in urinary sensation.

    Measured: Baseline and Weeks 4, 8, and 12

  11. Percentage of Participants Who Were Incontinent at Baseline and Became Dry

    Percentage of participants who had at least 1 UUI episode during baseline period and were dry (no UUI episodes) in the 3 days prior to study visits at week 8 and 12. UUI episodes defined as those with USS rating of 5 (unable to hold; leak urine) in the diary.

    Measured: Weeks 8 to 12

  12. Change From Baseline in Number of Skin Protective Agents Used by Participants at Weeks 4, 8, and 12

    Skin protective agents included incontinence pads, barrier creams, and powders. Change = observation minus baseline, where lower scores were an improvement/decrease in protective skin agents used.

    Measured: Baseline and Weeks 4, 8, and 12

  13. Percentage of Participants With Improvement at Week 12

    Patient Treatment Benefit Scale (PTBS): single-item scale assessed fesoterodine efficacy and safety in participants with overactive bladder. Participants asked to compare their present condition with their condition before start of trial: "My condition has been: 1=Greatly Improved; 2=Improved; 3=Not Changed; 4=Worsened, During Treatment." Improvement was defined as a rating of 1 or 2.

    Measured: Week 12

  14. Change From Baseline in Patient Perception of Bladder Condition (PPBC) at Week 4

    PPBC: self-administered, single-item, questionnaire that asked participants to describe their perception of their bladder-related problems. PPBC assessment rated on a 6-point scale: 1=no problems at all, 2=some very minor problems, 3=some minor problems, 4=moderate problems, 5=severe problems, 6=many severe problems. Change = observation minus baseline. Results categorized as Deterioration (score difference ≥1), No Change (score difference=0), Improvement (score difference less than [<]0).

    Measured: Baseline and Week 4

  15. Change From Baseline in PPBC at Week 8

    PPBC: self-administered, single-item, questionnaire that asked participants to describe their perception of their bladder-related problems. PPBC assessment rated on a 6-point scale: 1=no problems at all, 2=some very minor problems, 3=some minor problems, 4=moderate problems, 5=severe problems, 6=many severe problems. Change = observation minus baseline. Results categorized as Deterioration (score difference ≥1), No Change (score difference=0), Improvement (score difference <0).

    Measured: Baseline and Week 8

  16. Change From Baseline in PPBC at Week 12

    PPBC: self-administered, single-item, questionnaire that asked participants to describe their perception of their bladder-related problems. PPBC assessment rated on a 6-point scale: 1=no problems at all, 2=some very minor problems, 3=some minor problems, 4=moderate problems, 5=severe problems, 6=many severe problems. Change = observation minus baseline. Results categorized as Deterioration (score difference ≥1), No Change (score difference=0), Improvement (score difference <0).

    Measured: Baseline and Week 12

  17. Change From Baseline in PPBC at Week 24

    PPBC: self-administered, single-item, questionnaire that asked participants to describe their perception of their bladder-related problems. PPBC assessment rated on a 6-point scale: 1=no problems at all, 2=some very minor problems, 3=some minor problems, 4=moderate problems, 5=severe problems, 6=many severe problems. Change = observation minus baseline. Results categorized as Deterioration (score difference ≥1), No Change (score difference=0), Improvement (score difference <0).

    Measured: Baseline and Week 24

  18. Change From Baseline Patient Perception of Urgency Scale (PPUS) at Week 4

    PPUS: self-administered, single-item, questionnaire that measured the participant's perception of urinary urgency. It was sensitive to changes in perceptions of urinary urgency over time. Scale of 0 (usually not able to hold urine), 1 (usually able to hold urine [without leaking] until reaching toilet if go to toilet immediately), or 2 (usually able to finish what he/she was doing before going to toilet [without leaking]). Change = observation minus baseline. Improvement in PPUS defined as increase of 1 or more points in difference of scores relative to baseline.

    Measured: Baseline and Weeks 4

  19. Change From Baseline in PPUS at Week 8

    PPUS: self-administered, single-item, questionnaire that measured the participant's perception of urinary urgency. It was sensitive to changes in perceptions of urinary urgency over time. Scale of 0 (usually not able to hold urine), 1 (usually able to hold urine [without leaking] until reaching toilet if go to toilet immediately), or 2 (usually able to finish what he/she was doing before going to toilet [without leaking]). Change = observation minus baseline. Improvement in PPUS defined as increase of 1 or more points in difference of scores relative to baseline.

    Measured: Baseline and Week 8

  20. Change From Baseline in PPUS at Week 12

    PPUS: self-administered, single-item, questionnaire that measured the participant's perception of urinary urgency. It was sensitive to changes in perceptions of urinary urgency over time. Scale of 0 (usually not able to hold urine), 1 (usually able to hold urine [without leaking] until reaching toilet if go to toilet immediately), or 2 (usually able to finish what he/she was doing before going to toilet [without leaking]). Change = observation minus baseline. Improvement in PPUS defined as increase of 1 or more points in difference of scores relative to baseline.

    Measured: Baseline and Week 12

  21. Change From Baseline in PPUS at Week 24

    PPUS: self-administered, single-item, questionnaire that measured the participant's perception of urinary urgency. It was sensitive to changes in perceptions of urinary urgency over time. Scale of 0 (usually not able to hold urine), 1 (usually able to hold urine [without leaking] until reaching toilet if go to toilet immediately), or 2 (usually able to finish what he/she was doing before going to toilet [without leaking]). Change = observation minus baseline. Improvement in PPUS defined as increase of 1 or more points in difference of scores relative to baseline.

    Measured: Baseline and Week 24

  22. Change From Baseline in Overactive Bladder Satisfaction Questionnaire (OAB-q) Symptom/Bother Score at Weeks 4, 8, 12, and 24

    OAB-q: self-administered, 33-item, questionnaire assessed how much participant was bothered by selected bladder symptoms during previous week. Each item rated by participant on Likert scale 1 (least symptom bother) to 6 (most symptom bother). Raw scores transformed to a score from 0-100 where higher scores represented less favorable outcome. Change = baseline minus observation and higher scores were an improvement.

    Measured: Baseline and Weeks 4, 8, 12, and 24

  23. Change From Baseline in Overactive Bladder Satisfaction Questionnaire (OAB-q) Total Score at Weeks 4, 8, 12, and 24

    OAB-q: self-administered, 33-item, questionnaire assessed how much participant was bothered by selected bladder symptoms during previous week. Each item rated by participant on Likert scale 1 (least symptom bother) to 6 (most symptom bother). Raw scores transformed to a score from 0-100 where higher scores represented less favorable outcome. Change = observation minus baseline and higher scores were an improvement.

    Measured: Baseline and Weeks 4, 8, 12, and 24

  24. Change From Baseline in OAB-q Subscale Scores at Weeks 4, 8, 12, and 24

    OAB-q: self-administered, 33-item, questionnaire assessed how much participant bothered by bladder symptoms during previous week. Each item rated by participant on Likert scale 1 (least symptom bother) to 6 (most symptom bother). Raw scores transformed to 0-100 score where higher scores were less favorable outcome. Questions 1-8 constituted symptom severity/bother score. Questions 9-33 constitute HRQL component, which included domains of coping, concern, sleep, and social function. Change = observation minus baseline and higher scores were an improvement.

    Measured: Baseline and Weeks 4, 8, 12, and 24

  25. Change From Week 12 in Overactive Bladder Satisfaction (OAB-S) Scale for Satisfaction With OAB Control at Week 24

    OAB-S: validated self-administered instrument that evaluated OAB medication expectations, daily life with OAB, and satisfaction with OAB medication and included 3 stand-alone items that assessed overall expectation, satisfaction, and willingness to continue treatment. Satisfaction coded on scale of 1-5: (1-very satisfied to 5-very dissatisfied). Coding reversed algorithmically and results transformed: total score range 0-100. Higher final response value associated with better satisfaction. Change = score at Week 24 minus score at Week 12 where higher scores indicated better satisfaction.

    Measured: Weeks 12 and 24

  26. Change From Week 12 in OAB-S Scale for OAB Medication Expectation at Week 24

    OAB-S: evaluated OAB medication expectations, daily life with OAB, and satisfaction with OAB medication. Included 3 stand-alone items that assessed overall expectation, satisfaction, and willingness to continue treatment. Medication expectation coded on scale 1=Greatly exceeds my expectations to 5=Does not meet my expectations at all. Coding reversed by subtracting initial response value from 6, so higher final response value associated with better fulfilment of OAB medication expectations.

    Measured: Weeks 12 and 24

  27. Change From Baseline in King's Health Questionnaire (KHQ) Domain Scores at Week 12

    KHQ: self-administered questionnaire contained 21 questions scored in 9 domains (general health perception, incontinence impact, role limitations, physical limitations, social limitations, personal relationships, emotions, sleep/energy, severity of urinary symptoms). Range: 0-100, where 0=best outcome/response and 100=worst outcome/response. Change = observation minus baseline, where lower scores indicated better outcome/response.

    Measured: Baseline and Week 12

  28. Change From Baseline in EQ-5D- Health State Profile Utility Score at Week 12

    EQ-5D: participant rated questionnaire to assess HRQL in terms of single index value. Visual Analogue Scale (VAS) component rated current health state on scale from 0 (worst imaginable health state) to 100 (best imaginable health state). For each question, scores categorized into 3 levels of response, level 1=no health problems, 2=some problems and 3= extreme problems, and health state profile utility score derived from these, which could range from 1 prefect health to -0.594 worst possible health. Change = observation minus baseline, where higher scores indicated a better health state.

    Measured: Baseline and Week 12

  29. Change From Baseline in EQ-5D- Each Dimension Score at Week 12

    EQ-5D: participant rated questionnaire to assess HRQL in terms of a single utility score. Health State Profile component assessed level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicated better health state; 3 indicated worst health state. Scoring formula assigned utility value for each domain in profile. Score was transformed and results in total score could have ranged from -0.594 to 1.000; Change = observation minus baseline, where higher scores indicated a better health state.

    Measured: Baseline and Week 12

  30. Change From Baseline in Mini Mental State Examination (MMSE) at Week 12

    MMSE measured general cognitive functioning: orientation, memory, attention, calculation, language, visuospatial functions. Total score derived from sub-scores; total ranged from 0 - 30, higher score indicated better cognitive state. Change = observation minus baseline where higher scores indicated better cognitive functioning.

    Measured: Baseline and Week 12

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Nov 2008 (estimated)
  2. Study startJun 2008
  3. Primary completionSep 2010
  4. Study completionSep 2010

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
794 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00798434
Sponsor's protocol ID
A0221045
Acronym
SOFIA
Status last verified
Nov 2011
First submitted
25 Nov 2008
Last updated
14 Dec 2011
Data monitoring committee
No

Publications

  • Stoniute A, Madhuvrata P, Still M, Barron-Millar E, Nabi G, Omar MI. Oral anticholinergic drugs versus placebo or no treatment for managing overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2023 May 9;5(5):CD003781. doi: 10.1002/14651858.CD003781.pub3.

    PubMed 37160401
  • Wagg A, Khullar V, Michel MC, Oelke M, Darekar A, Bitoun CE. Long-term safety, tolerability and efficacy of flexible-dose fesoterodine in elderly patients with overactive bladder: open-label extension of the SOFIA trial. Neurourol Urodyn. 2014 Jan;33(1):106-14. doi: 10.1002/nau.22383. Epub 2013 Mar 4.

    PubMed 23460503

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Fesoterodine fumarate in people with Urinary Bladder, Overactive, run by Pfizer at 60 sites in 15 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 14 Dec 2011. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 60 sites in United Kingdom, Germany, Sweden, Finland, Portugal and 10 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 14 Dec 2011). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From Baseline in Number of Micturition-Related Urgency Episodes Per 24 Hours at Week 12 (time frame: Baseline and Week 12). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00798434, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Dec 2011.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in